Flu vaccine makers begin initial shipments for upcoming season

Between October 2023 and June 2024, the CDC estimated there were between 35 million and 65 million flu cases in the United States. As summer continues, influenza vaccine manufacturers are already busy preparing for the upcoming flu season this fall.

CSL Seqirus announced that it started shipping influenza vaccines on July 9. The company is distributing three different vaccines: Flucelvax, Fluad, and Afluria. Flucelvax is noted as the first and only cell-based influenza vaccine available, while Fluad is recommended by the CDC's Advisory Committee on Immunization Practices for individuals aged 65 and older. Afluria is an egg-based vaccine suitable for those six months and older. Gregg Sylvester, M.D., chief health officer at CSL Seqirus, emphasized the importance of maintaining high vaccination rates to mitigate influenza-related illnesses and severe outcomes.

Statistics from the previous flu season in the U.S. indicated a decline in vaccination rates along with an increase in flu-related hospitalizations and deaths, according to CSL Seqirus, which cited preliminary CDC data.

Sanofi also began its vaccine shipments on July 10, with additional shipments scheduled through October. Sanofi's flu vaccine portfolio for the 2024/2025 season includes Flublok, a quadrivalent shot made using insect cells, and various versions of Fluzone, both standard and high-dose.

GSK started its vaccine shipments on July 11, following FDA licensing and lot-release approval. According to the company, they expedited the production and distribution process following the vaccine strain recommendations made in February. GSK's flu vaccines—Flulaval and Fluarix—are expected to see over 36 million doses distributed across the U.S. this season.

CSL Seqirus advises vaccination ahead of the flu season, ideally in September or October for those who need only one dose, as it takes about two weeks post-vaccination for antibodies to develop and combat the flu. The CDC recommends that everyone aged six months and older get an annual flu vaccine, especially individuals at higher risk of severe complications, such as older adults, pregnant individuals, and children under five years old.

With flu season approaching, the efforts of these pharmaceutical companies aim to reduce the impact of influenza on public health by ensuring widespread vaccine availability and encouraging high vaccination rates.